how to inject glp-1 Injection Sites: Where and How to Perform Injections for

PubMed:9849822 Andersen, N.B., et al

Compound class Synthetic cyclic melanocortin peptide Primary therapeutic relevance Central sexual-desire signaling Approved product VYLEESI bremelanotide injection FDA approval date June 21, 2019 Approved population Premenopausal women with acquired, generalized HSDD Not approved for Men, postmenopausal women, ED, or performance enhancement Terminology clarification: PT-141 generally refers to bremelanotide free base or the active peptide, while the approved drug product contains bremelanotide acetate in a specific sterile injectable formulation

No significant organ toxicity has been observed in standard histological analyses of animals treated with therapeutic-range doses

MU-ACUC (VM.R.25.10.248)